Research Projects All Projects
Projects

Quick links

European Regional Development Fund (ERDF), Measure 1.1.1.1 “Support for applied research”

Funding: European Regional Development Fund (ERDF), Measure 1.1.1.1 “Support for applied research”

Project No.: 1.1.1.1/20/A/126

Period: 1 March 2021 – 30 November 2023

Project costs: 540 540.54 EUR

Principle Investigator: Dr. biol. Jānis Kloviņš

Cooperation partner: SIA “Latvia MGI Tech” 

 

Project summary:

This project aims is to create the first Latvian genome variation reference and estimate the accurate, population-specific PRS for the metabolic disease using the national biobank, the Genome Database of Latvian Population (LGDB) resource establishing a functional framework for -omics based personalised prevention and treatment program in Latvia.

The aim of our project is to create the first Latvian genome variation reference and estimate the accurate, population-specific polygenic risk scores (PRS) for the metabolic disease using the national biobank the Genome Database of Latvian Population resource establishing a functional framework for -omics based personalised prevention and treatment program in Latvia. The project will have a great impact on the further development of genomics-based medicine in Latvia and resources created in the frame of this project will also be available for the whole research community. More specifically, we will target diabetes and produce validated optimal polygenic risk scores for this type 2 diabetes and other metabolic parameters and will use this information to search for novel biomarkers or possible patient subgroups that would benefit from the knowledge of their genetics.

Information published 01.03.2021.

 

Progress of the project:

1 March 2021 – 31 May 2021

In the first quarter of the project, cohort selection is performed using the resources of the Genome database of Latvian population, including individuals representing the general population, patients with type 2 diabetes within the OPTOMED cohort, patients with type 2 diabetes outside the OPTIMED cohort with additional longitudinal samples and MODY patients. The clinical parameters that will be obtained from the health data registries are selected in order to supplement the range of related data available in the Genome database of Latvian population. In addition, selection of DNA samples and quality control are performed for the preparation of the next generation of sequencing libraries.

Information published 31.05.2021.



Mājas lapas izstrādi finansēja ERAF 2.1.1.2. aktivitātes projekts Nr. 2010/0196/2DP/2.1.1.2.0/10/APIA/VIAA/004 "Latvijas biomedicīnas pētījumu integrācija Eiropas zinātnes telpā".